Microphthalmia-anophthalmia-coloboma is a rare genetic condition that affects eye development before birth. People with microphthalmia-anophthalmia-coloboma may have very small eyes, missing eyes, or gaps in eye structures called colobomas, and vision can range from near normal to severe vision loss or blindness. Signs are usually recognized during pregnancy ultrasounds, at birth, or in early infancy, and the condition is lifelong. Many living with microphthalmia-anophthalmia-coloboma also have related features like unusual eye movements, light sensitivity, or need for vision supports, and some may have differences in facial, ear, or growth patterns. Care focuses on regular eye and pediatric visits, low-vision services, protective eyewear, and sometimes surgery for specific eye features, and life expectancy is usually typical unless other serious medical problems are present.
Overview
Microphthalmia-anophthalmia-colobomaSymptoms
Microphthalmia-anophthalmia-coloboma involves small or missing eyes and eye gaps (colobomas), usually recognized before or at birth. Features include low vision to blindness, light sensitivity, and nystagmus. Some have facial differences, cleft lip/palate, or organ anomalies; early symptoms of Microphthalmia-anophthalmia-coloboma vary.
Outlook and prognosis
Many living with Microphthalmia-anophthalmia-coloboma build full, rich lives, though vision ranges from near‑normal to severe impairment. Early low‑vision support, protective eyewear, and school accommodations help independence. Regular eye and developmental check-ins guide treatment as needs change.
Causes and risk factors
Microphthalmia-anophthalmia-coloboma often stems from genetic changes—sometimes inherited (dominant or recessive), sometimes new—or chromosomal differences. Risk rises with certain prenatal exposures or conditions, including isotretinoin/retinoic acid, alcohol, maternal diabetes, and infections (rubella, CMV, toxoplasmosis). Consanguinity may increase recessive risk.
Genetic influences
Genetics play a major role in Microphthalmia-anophthalmia-coloboma, with many cases linked to single-gene variants or chromosomal changes. Inheritance can be autosomal dominant, autosomal recessive, or X-linked, though some cases are new (de novo). Genetic testing helps clarify cause, recurrence risk, and family planning.
Diagnosis
Doctors usually recognize microphthalmia‑anophthalmia‑coloboma from clinical features at birth or on prenatal ultrasound, then confirm with eye imaging. Genetic tests help define cause and guide care; many families pursue genetic diagnosis of microphthalmia‑anophthalmia‑coloboma.
Treatment and drugs
Treatment for Microphthalmia-anophthalmia-coloboma focuses on vision support, eye protection, and related developmental care. Plans may include protective shells or prosthetic eyes, low-vision aids, cataract or eyelid surgery when helpful, and early therapy for learning and mobility. Regular follow-up with eye, genetics, and pediatric teams guides adjustments over time.
Symptoms
Most noticeable are differences in eye size or shape and how well someone sees. Microphthalmia-anophthalmia-coloboma is present from birth and can involve small or missing eyes or gaps in eye structures. Features vary from person to person and can change over time. Parents often notice early features of Microphthalmia-anophthalmia-coloboma at or soon after birth, such as a small-looking eye or a keyhole-shaped pupil.
One or both eyes are smaller than average (microphthalmia). Size can range from slightly small to very underdeveloped and may limit vision. Socket expanders and glasses may be part of care.
One or both eyes are absent (anophthalmia). The eye socket may be small and need gradual shaping with conformers. A prosthetic eye can help appearance and support socket growth.
A gap in the iris, retina, or optic nerve (coloboma). It can look like a keyhole-shaped pupil when the iris is involved. Vision impact depends on which structures are affected.
In Microphthalmia-anophthalmia-coloboma, vision ranges from near-normal to severe impairment or blindness. One eye may see better than the other. Low-vision aids and early vision support can maximize remaining sight.
How people usually first notice Microphthalmia-anophthalmia-coloboma?
Parents and clinicians often first notice the first signs of microphthalmia–anophthalmia–coloboma at birth or on the newborn exam, when one or both eyes look smaller than expected, appear missing, or have a keyhole‑shaped pupil opening from a coloboma. Sometimes prenatal ultrasound or fetal MRI raises the first concern by showing unusually small eye structures or absent ocular tissue, leading to closer newborn evaluation. In the first weeks, families may also notice light sensitivity, unusual eye movements, or limited visual response, which prompts referral to pediatric ophthalmology and genetics to confirm how MAC is first noticed and plan care.
Types of Microphthalmia-anophthalmia-coloboma
Microphthalmia-anophthalmia-coloboma (MAC) has several well-recognized clinical variants that describe how the eyes formed and which structures are affected. These variants can occur in one or both eyes and may appear on their own or as part of a broader genetic syndrome. Vision ranges from near-normal to severe vision loss depending on the variant and its extent. People may notice different sets of symptoms depending on their situation.
Anophthalmia
One or both eyes are absent. This often causes severe vision loss and noticeable changes to the eye socket and eyelids. It may be isolated or part of a genetic syndrome.
Microphthalmia
One or both eyes are smaller than usual. Vision can range from mild reduction to severe impairment depending on how developed the eye structures are. Some people also have a small opening in the iris or retina.
Coloboma
A gap or cleft in eye structures such as the iris, retina, or optic nerve. Vision changes depend on location—iris coloboma may mainly affect light sensitivity, while retinal or optic nerve coloboma can reduce central or peripheral vision. Sometimes only one eye is affected.
Unilateral versus bilateral
Only one eye (unilateral) or both eyes (bilateral) are involved. Bilateral MAC tends to cause more significant vision challenges and may be linked to genetic syndromes more often. Unilateral MAC may allow stronger overall vision if the other eye is typical.
Isolated versus syndromic
Eye findings occur alone (isolated) or with features in other organs (syndromic). Syndromic forms can include differences in growth, brain development, hearing, heart, or kidneys depending on the underlying gene. Knowing the type helps guide genetic testing and care planning.
Genetic subtypes
Changes in several genes (such as SOX2, OTX2, STRA6, PAX6) are known to cause different variants of MAC. Specific genes may be more associated with anophthalmia, severe bilateral microphthalmia, or coloboma, and can influence severity and associated features. Discussing types of MAC with a genetics team can clarify prognosis and family planning options.
What genetics can tell you about symptoms
Some genetic changes in SOX2, OTX2, or PAX6 can disrupt early eye formation, leading to very small eyes (microphthalmia), missing eyes (anophthalmia), or gaps in eye structures (coloboma). Depending on the gene, people may also have vision loss, eyelid differences, or developmental delays.
Causes and risk factors
Most cases arise from changes in genes that guide early eye development, which can be inherited or happen as a new mutation. Risk factors for Microphthalmia-anophthalmia-coloboma include a family history, chromosomal differences, and sometimes being part of a broader syndrome. During pregnancy, alcohol and certain medicines used for acne or seizures can raise risk. Poorly controlled diabetes, severe vitamin A deficiency, and some viral infections in pregnancy can add to risk. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Microphthalmia-anophthalmia-coloboma develops very early in pregnancy, so risk factors mostly relate to that time window. Risk factors for microphthalmia-anophthalmia-coloboma include health conditions in the pregnant body and outside exposures that can interfere with eye formation. Doctors often group risks into internal (biological) and external (environmental). Not every pregnancy with a known exposure leads to this condition, but mapping patterns helps explain why risk can be higher in some situations.
Certain infections in the first trimester can disrupt eye formation. Examples include rubella (German measles), cytomegalovirus, varicella (chickenpox), toxoplasmosis, and Zika. When these occur early, the chance of microphthalmia-anophthalmia-coloboma is higher.
Retinoid medicines, such as isotretinoin for severe acne, can cause serious birth differences if taken around conception or in early pregnancy. Even brief exposure during the first weeks has been linked to microphthalmia or coloboma. These are among the stronger environmental risk factors for microphthalmia-anophthalmia-coloboma.
Some other medicines known to harm fetal development, such as thalidomide or methotrexate, have been associated with eye formation problems. Risk depends on dose and timing, with the greatest concern in the first 6–10 weeks.
Significant ionizing radiation to the abdomen or pelvis early in pregnancy can increase risk. This exposure is uncommon and usually relates to radiation therapy or severe accidents, not routine imaging. The most sensitive window is the first trimester when eyes are forming.
Genetic risk factors
Microphthalmia-anophthalmia-coloboma often stems from changes in genes that guide early eye development. Carrying a genetic change doesn’t guarantee the condition will appear. Variants can be inherited in families or arise for the first time in a child, and testing can sometimes pinpoint the exact gene involved.
SOX2 variants: Changes in the SOX2 gene are a leading genetic cause of Microphthalmia-anophthalmia-coloboma, especially with both eyes affected. Many changes are de novo rather than inherited.
OTX2 variants: Alterations in OTX2 can cause microphthalmia or anophthalmia with or without coloboma. Effects range from isolated eye differences to broader developmental features.
PAX6 variants: While best known for aniridia, PAX6 changes can also contribute to microphthalmia or coloboma in some families. The severity can differ widely between relatives.
CHD7 variants: CHD7 changes can lead to coloboma as part of CHARGE syndrome, a genetic condition that often includes other findings. This genetic cause of Microphthalmia-anophthalmia-coloboma may be inherited or de novo.
BCOR variants: Changes in BCOR cause an X-linked form known as Lenz microphthalmia. Males are typically more affected, while females may be carriers with mild or no eye findings.
ALDH1A3 variants: Recessive changes in ALDH1A3 are a well-recognized cause of severe bilateral microphthalmia. They are more often found in families with shared ancestry or where parents are related.
STRA6 variants: Recessive variants in STRA6 can lead to anophthalmia or severe microphthalmia and may occur alongside other organ differences. Genetic testing can confirm the diagnosis and guide family counseling.
Other genes: Variants in RAX, VSX2, FOXE3, BMP4, GDF6, PRSS56, MFRP and others have been linked to Microphthalmia-anophthalmia-coloboma. A panel or exome test can survey these many genes at once.
Chromosomal changes: Deletions or duplications that include eye-development genes (for example near SOX2 on 3q or OTX2 on 14q) can cause Microphthalmia-anophthalmia-coloboma. Larger chromosome alterations, such as 13q deletions, can also be involved.
Inheritance patterns: This condition can be autosomal dominant, autosomal recessive, or X-linked depending on the gene. Knowing the pattern refines recurrence risk for future pregnancies.
De novo changes: Many children with the condition have a variant that arose for the first time in them. Recurrence risk for siblings is usually low but not zero.
Parental mosaicism: A parent may carry the variant in a small fraction of cells without obvious signs. This hidden mosaicism can increase the chance of having another affected child.
Variable expressivity: The same genetic change can cause different eye findings within the same family. This helps explain why early symptoms of Microphthalmia-anophthalmia-coloboma vary from subtle to more severe.
Reduced penetrance: Some people who carry a family variant show little or no eye difference. Relatives can still pass the variant to children who may be affected.
Consanguinity: Parents who are biologically related have a higher chance of carrying the same rare recessive variant. This raises the likelihood of recessive forms of the condition in their children.
Lifestyle risk factors
Lifestyle habits do not cause Microphthalmia-anophthalmia-coloboma, but daily choices can influence comfort, safety, and how complications are managed over time. This overview focuses on how lifestyle affects Microphthalmia-anophthalmia-coloboma in practical ways. In particular, it highlights lifestyle risk factors for Microphthalmia-anophthalmia-coloboma that may worsen eye strain, injury risk, or functional vision challenges. Tailored routines can help protect the remaining ocular structures and support independence.
Consistent use of sunglasses and brimmed hats can reduce glare and photophobia from coloboma-related light scatter. Managing indoor lighting with task lamps and dimmers may improve contrast and reduce visual fatigue.
Avoiding high-impact or contact sports lowers the risk of trauma that could trigger retinal detachment in eyes with coloboma. Wearing protective eyewear during activities like cycling or home repairs adds an extra safety layer.
Daily cleaning of ocular prostheses and eyelids reduces irritation and infection risk. Following care routines helps maintain comfort and fit over time.
Using large print, high-contrast settings, and taking regular breaks can limit eye strain in individuals with residual vision. Proper viewing distance and magnification tools help sustain reading and learning tasks.
Risk prevention
Microphthalmia-anophthalmia-coloboma (MAC) happens during early fetal development, so full prevention isn’t always possible. Some steps before and during pregnancy can lower risk, and early planning can reduce complications for a baby who is affected. Some prevention is universal, others are tailored to people with specific risks. Learning the early symptoms of microphthalmia-anophthalmia-coloboma can also help families seek care quickly and protect any existing vision.
If there’s a family history or a previous child with MAC, meet with a genetics professional before pregnancy. They can discuss inheritance, carrier testing, and options for prenatal or preimplantation testing.
Review all prescription and over-the-counter medicines before conception, especially acne drugs containing retinoids like isotretinoin and high-dose vitamin A supplements. Using safer alternatives and careful contraception planning can lower MAC risk in a future pregnancy.
Make sure vaccinations are up to date before pregnancy, especially for rubella, and follow hygiene steps to reduce cytomegalovirus and toxoplasma exposure. Handwashing, avoiding undercooked meat, and leaving cat litter changes to someone else can lower infection-related risks to eye development.
If you live with diabetes, aim for stable blood sugar before conception and throughout pregnancy. Good control lowers the chance of birth defects, including problems with eye formation.
Transmission
Microphthalmia-anophthalmia-coloboma (MAC) is not contagious; it cannot be caught or spread between people. Many cases happen because of a new change in a gene very early in development, with no prior family history.
When it does run in families, genetic transmission of Microphthalmia-anophthalmia-coloboma can follow different patterns: autosomal dominant (an affected parent has a 1 in 2, or 50%, chance for each child), autosomal recessive (two carrier parents have a 1 in 4, or 25%, chance), or, less often, X-linked (often passed on by a carrier mother). Sometimes changes in chromosomes are involved. A genetics team can explain how Microphthalmia-anophthalmia-coloboma is inherited in your family and discuss the chance of it happening again.
When to test your genes
Test your genes if you or your child has microphthalmia, anophthalmia, or coloboma, especially when both eyes are affected, other birth differences are present, or there’s a family history. Genetic testing can clarify the cause, guide eye and developmental care, and refine recurrence risks for future pregnancies. Consider testing before pregnancy or early in infancy.
Diagnosis
Early signs often show at birth or during the first eye check, when one or both eyes look smaller, missing, or with a keyhole-like notch in the iris. The genetic diagnosis of Microphthalmia-anophthalmia-coloboma usually combines a careful eye exam with imaging and genetic tests to confirm the cause and guide care. A detailed family and health history can help identify patterns that suggest an inherited form.
An eye specialist looks at the size and shape of the eyes, the pupils’ light reflex, and the iris and eyelids. They note features such as a small or absent eye or a keyhole-shaped gap that suggests a coloboma.
With special light and drops to widen the pupil, doctors examine the cornea, lens, and retina. This helps map how far a coloboma extends and whether other eye structures are involved.
Sound waves create images when the eye is too small or cloudy to see inside directly. It helps confirm whether eye tissue is present and checks the lens, retina, and optic nerve area.
MRI shows detailed pictures of the eye sockets, optic nerves, and brain without radiation. It can reveal associated brain differences and helps plan care or surgery if needed.
Stages of Microphthalmia-anophthalmia-coloboma
Microphthalmia-anophthalmia-coloboma does not have defined progression stages. These eye differences are present from birth and vary widely from person to person, so doctors describe the specific features in each eye rather than a stepwise decline. Different tests may be suggested to help confirm the diagnosis, such as a careful eye exam, ultrasound or imaging, and sometimes genetic testing. Parents and clinicians usually notice early symptoms of Microphthalmia-anophthalmia-coloboma soon after birth, and ongoing care focuses on vision checks, eye pressure screening, and support like glasses, patching, or prosthetic shaping as the child grows.
Outlook and prognosis
Looking at the long-term picture can be helpful. For most people with Microphthalmia-anophthalmia-coloboma (MAC), life expectancy is usually near typical unless there are additional syndromic features affecting the brain, heart, kidneys, or other organs. Vision ranges from near-normal to no light perception, and that range shapes daily life more than the diagnosis itself. Early care can make a real difference, from protective eyewear and patching to low-vision tools, orientation and mobility training, and, when needed, prosthetic eyes to support socket growth and facial symmetry. Many people find that symptoms stabilize after early childhood, though vision can change if there are complications like glaucoma, retinal detachment, or cataract—conditions that can often be monitored and treated.
The outlook is not the same for everyone, but progress in pediatric eye care and vision rehabilitation means many with MAC attend mainstream schools, read with magnification or audio, and navigate workplaces with adaptive tech. When thinking about the future, it helps to plan for regular eye checks to catch issues early, since early symptoms of Microphthalmia-anophthalmia-coloboma complications—such as eye pain, sudden light flashes, or new floaters—may signal something urgent like a detachment. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, and some children with MAC have a genetic change that also affects development or growth; in those cases, therapies like physiotherapy, speech therapy, and educational support can improve independence. Severe complications that threaten overall health are uncommon in isolated MAC, but they can occur in syndromic forms, so your care team may recommend heart, kidney, or hearing evaluations to be safe.
Knowing what to expect can ease some of the worry. With ongoing care, many people maintain independence, build strong travel and reading skills, and participate fully in school, work, and family life. Talk with your doctor about what your personal outlook might look like, including vision goals, safety planning, and whether genetic testing could clarify risks for you or future children. Genetic testing can sometimes provide more insight into prognosis, and not everyone with the same gene change will have the same outlook.
Long-term effects
Living with vision differences can shape daily life from infancy through adulthood. Long-term effects vary widely. The early features of Microphthalmia-anophthalmia-coloboma can influence how children learn to move through space and interact with others, and some effects remain into adult years. Over time, the long-term picture is often a mix of stable eye structure differences and risks for specific complications tied to the original eye findings.
Sight can span from near-normal clarity to severe vision loss or blindness. Many live with useful vision in one eye and reduced vision in the other.
Reduced 3D depth cues can make judging steps, curbs, or reaching for objects harder. People may rely more on touch and motion to gauge distance.
Some have gaps in side or central vision, especially with coloboma. This can affect navigation in crowded spaces and noticing hazards off to the side.
Strabismus and nystagmus can persist over time. Head tilts or turns may develop to find a clearer or steadier view.
How is it to live with Microphthalmia-anophthalmia-coloboma?
Living with microphthalmia–anophthalmia–coloboma often means navigating partial to complete vision loss in one or both eyes, which can affect reading, depth perception, mobility, and facial appearance. Daily life may involve low-vision tools, orientation and mobility training, protective eyewear, and regular eye and medical care; many also work with early intervention, special education, and occupational therapy to build skills and independence. Families, classmates, and coworkers may need simple adjustments—good lighting, clear walkways, large-print materials, and patience with new environments—and open conversations can ease social misunderstandings about eye contact or appearance. Many find a strong community through vision services and peer support, and with the right accommodations, people build routines, careers, and relationships that reflect their goals, not just their diagnosis.
Treatment and drugs
Treatment for microphthalmia–anophthalmia–coloboma focuses on vision support, eye protection, and addressing related needs rather than “curing” the eye formation differences. Care often starts in infancy with protective measures such as custom conformers or prosthetic shells to support socket growth, glasses with safety lenses, patching for amblyopia (lazy eye) when useful, and low-vision services to build visual skills. As children grow, specialists may offer surgeries to improve eyelid or socket shape, fit prosthetic eyes more comfortably, or repair certain colobomas if anatomy allows, while screening for and treating complications like glaucoma, cataract, or retinal problems. Alongside medical treatment, lifestyle choices play a role, including early vision therapy, orientation and mobility training, classroom accommodations, and UV-blocking eyewear to protect sensitive eyes. It’s common to try more than one medication before finding the right plan for issues like eye pressure or dryness, and your care team may also coordinate genetic counseling and multispecialty support if there are associated health or developmental concerns.
Non-drug treatment
Living with Microphthalmia-anophthalmia-coloboma often means finding practical ways to protect vision, support development, and build confidence in daily life. Non-drug treatments often lay the foundation for long-term progress, from early therapies to school supports and specialty eyewear. Care usually evolves over time, matching a child’s growth and any changes in vision. Families can expect a team-based approach with eye specialists, therapists, educators, and genetic counselors working together.
Specialized eye therapists teach skills to make the most of remaining sight. This can include contrast and lighting tips, magnification, and reading strategies.
Therapists support motor, speech, and visual skills in infancy and toddlerhood. Early symptoms of Microphthalmia-anophthalmia-coloboma can prompt referral to services that boost development.
Training helps children and adults move safely at home, school, and outdoors. Techniques cover navigation, glare management, and when useful, cane skills.
Covering the stronger eye can help the weaker eye work harder and improve function. Your eye care team will guide how many hours per day and for how long.
Your genes may have an impact on how drugs work for you
Even when two children share the same eye findings in microphthalmia–anophthalmia–coloboma, their genes can change how they process medications, altering dose needs and side‑effect risks. Pharmacogenetic testing and careful monitoring help tailor treatments more safely and effectively.
Pharmacological treatments
Medicines can’t change how the eye formed, but they can ease symptoms, protect the eye surface, and treat complications that sometimes come with Microphthalmia-anophthalmia-coloboma. Drugs that target symptoms directly are called symptomatic treatments. Some are used daily for comfort, while others are used short-term after procedures or when problems like high eye pressure occur. Early symptoms of Microphthalmia-anophthalmia-coloboma are structural, so medication focuses on comfort, protecting vision that’s present, and preventing complications.
Carboxymethylcellulose or hypromellose eye drops and petrolatum-based ointments keep the surface moist and comfortable. They can help people with Microphthalmia-anophthalmia-coloboma who use conformers or prosthetic shells. Use more often during dry, windy weather or long screen time.
Atropine 1% drops in the stronger eye can encourage use of the weaker eye when some vision is present. This may be used instead of or alongside patching. Light sensitivity and near blur can occur while the drop is working.
Timolol, latanoprost, or dorzolamide eye drops lower eye pressure if glaucoma develops in Microphthalmia-anophthalmia-coloboma. In urgent cases, oral acetazolamide may be added for short periods. Children need careful dosing and monitoring for side effects.
Prednisolone acetate or fluorometholone steroid drops calm inflammation, and ketorolac can help with pain after procedures. These are usually short-term to protect healing tissue. Doctors often taper steroid drops to avoid rebound inflammation and check eye pressure.
Genetic influences
Many cases of microphthalmia-anophthalmia-coloboma (MAC) stem from changes in the genes that guide early eye formation before birth. Genetics is only one piece of the puzzle, but it’s a major driver of MAC, whether the eye differences occur alone or as part of a broader syndrome. These gene changes may be inherited from a parent or can arise for the first time in a child; both single-gene changes and missing or extra sections of chromosomes have been found. When inherited, the pattern can vary—sometimes one altered copy from a parent is enough, and other times a child is affected only when both parents carry a gene change without symptoms. Features can differ widely, even within the same family, and a parent who carries a gene change may have mild signs or none at all. Genetic testing and counseling can help clarify the cause of MAC for your family, estimate the chance of MAC in a future pregnancy, and discuss options for prenatal screening. In practical terms, genetic testing for microphthalmia-anophthalmia-coloboma may identify the exact gene change or, if results are inconclusive, still refine the risk for relatives.
Is Microphthalmia-anophthalmia-coloboma genetic?
Genetics play a major role in Microphthalmia-anophthalmia-coloboma, with many cases linked to single-gene variants or chromosomal changes. Inheritance can be autosomal dominant, autosomal recessive, or X-linked, though some cases are new (de novo). Genetic testing helps clarify cause, recurrence risk, and family planning.
Pharmacogenetics—how genetics influence drug effects
There isn’t a medicine that can reverse Microphthalmia-anophthalmia-coloboma; care usually centers on surgeries, socket or eyelid expanders, vision support, and treating related health issues. When early symptoms of Microphthalmia-anophthalmia-coloboma prompt genetic testing, results can show whether it’s part of a broader syndrome, which may change which drugs are used or monitored (for example, hormone replacement if the pituitary is affected, or seizure medicines if the brain is involved). For medicines used around procedures—such as anesthesia, pain control, or antibiotics—your team may consider standard pharmacogenetic information to help choose and dose drugs more safely, though this testing isn’t specific to MAC. Genetics is only one factor in these decisions; age, other conditions, and how the liver and kidneys work also matter. In some families, findings that involve the vitamin A pathway can lead doctors to be extra cautious with retinoid-based drugs in the future or during pregnancy planning, and your clinician will tailor guidance to your situation.
Interactions with other conditions
Living with Microphthalmia-anophthalmia-coloboma often means managing vision differences alongside other health issues that can affect growth, learning, and daily communication. Certain diseases may “overlap,” meaning eye findings can occur together with hearing loss, heart or kidney differences, cleft palate, or brain development changes that raise the chance of developmental delays or seizures. In babies, early symptoms of Microphthalmia-anophthalmia-coloboma may show up alongside feeding difficulties, poor growth, or low blood sugar if hormone levels are affected. Eye-specific conditions like cataracts, glaucoma, or retinal problems can also occur and may interact with other diagnoses—combined hearing and vision challenges, for example, can make early communication and mobility training even more important. Some of these links reflect shared genetic causes, so when one condition is present, doctors may look for others in the same “family” of features, and offer genetic testing to guide care. Coordinated follow-up with eye specialists, hearing teams, cardiology, nephrology, endocrinology, and developmental services helps ensure treatments work together rather than at cross‑purposes.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described babies born with unusually small eyes, missing eyes, or gaps in the structures of the eye—what we now group together as microphthalmia-anophthalmia-coloboma (MAC). Midwives and families kept quiet notes of “one eye not opening” or a visible cleft in the colored part of the eye. In some communities, children were guided to sit near windows or bright courtyards so they could use any remaining vision for reading or craftwork. These everyday choices show how people worked around vision differences long before medical names were used.
First described in the medical literature as separate findings—“anophthalmia” for missing eyes, “microphthalmia” for abnormally small eyes, and “coloboma” for a gap in eye tissue—these features were initially treated as distinct conditions. By the late 19th and early 20th centuries, careful drawings and early photographs helped doctors recognize patterns: some children had just one feature, others had a combination. Over time, descriptions became more consistent, and clinicians realized these findings could occur together or as part of a broader syndrome affecting growth, hearing, or development.
With each decade, tools improved. The ophthalmoscope allowed doctors to see colobomas inside the eye, not just at the iris. Later, ultrasound in pregnancy and then fetal MRI made it possible to notice absent or very small eyes before birth. This shifted care earlier, giving families time to plan for support, eye prosthetics, or surgery to protect the eye socket and eyelids after delivery.
Advances in genetics in the late 20th and early 21st centuries changed the conversation again. Researchers found that MAC can result from many different genetic changes, some inherited and others new in a child. They also learned that infections during pregnancy or certain exposures can play a role in a small subset of cases. This helped explain why MAC looks so different from person to person—one child may have a small coloboma with near‑typical vision, while another may have no eye on one side and limited vision on the other.
In recent decades, knowledge has built on a long tradition of observation. Today’s care teams bring together eye doctors, clinical geneticists, and rehabilitation specialists to address both vision and facial development, reflecting lessons learned over centuries. Understanding this history helps explain why you may hear multiple terms and why doctors now talk about a spectrum. The path from scattered case notes to modern imaging and genetic testing has made MAC easier to recognize, name, and plan for—without losing sight of the individual needs of each child and adult living with it.